NVNO241115C5000
- 0.05
- 0.000.00%
enVVeno Medical Newsroom
10-Q: Q3 2024 Earnings Report
EnVVeno Medical Q3 EPS $(0.35) Misses $(0.33) Estimate
EnVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of This Year
EnVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating EnVVe(R)
Catalyst Watch: Tesla's Robotaxi Reveal, AI Events for Nvidia, AMD, and HP Enterprise
Correction: EnVVeno Medical Prices $15 Million Public Offering
Dow Surges Over 100 Points; Costco Earnings Top Views
Traders Digest Fed's Preferred Inflation Metric as US Equity Futures Waver Pre-Bell
Cassava Sciences, EnVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Top Premarket Decliners
EnVVeno Medical Stock Falls After It Prices $15M Securities Offering
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
12 Health Care Stocks Moving In Thursday's After-Market Session
EnVVeno Medical Corporation Announces Proposed Public Offering
EnVVeno Medical Adds Sandy Prietto to Its Executive Team as Vice President of Marketing
EnVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
Here's Why We're Not Too Worried About EnVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation
EnVVeno Medical Q2 2024 GAAP EPS $(0.31), Inline
EnVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
10-Q: Q2 2024 Earnings Report